About
Arbor Biotechnologies
Genetic medicines for genetic diseases
Arbor Biotechnologies is a clinical stage, next-generation gene editing company advancing a portfolio of first-in-class genomic medicines addressing serious diseases for which there are no existing functional cures, with a CNS pipeline initially prioritizing multiple ALS targets and a co-developed, clinical program, ABO-101, for the treatment of primary hyperoxaluria type 1. Our unique breadth of gene editing technologies goes beyond the limitations of early editing approaches to unlock access to new gene targets and expand the therapeutic reach of genomic medicines.
HQCambridge, United States